The sulfonylurea controversy: more questions from the heart.

Brady, P A; Terzic, A

Brady, P A; Terzic, A.

Affiliation

Brady PA; Department of Medicine, Mayo Clinic, Mayo Foundation, Rochester, Minnesota 55905, USA.

J Am Coll Cardiol ; 31(5): 950-6, 1998 Apr.

Article in En | MEDLINE | ID: mdl-9561992

Subject(s)

Diabetes Complications; Heart Diseases/complications; Heart/drug effects; Hypoglycemic Agents/pharmacology; Sulfonylurea Compounds/pharmacology; Animals; Diabetes Mellitus/physiopathology; Heart/physiopathology; Heart Diseases/drug therapy; Heart Diseases/physiopathology; Humans; Hypoglycemic Agents/therapeutic use; Ischemic Preconditioning, Myocardial; Pancreas/drug effects; Potassium Channel Blockers; Potassium Channels/drug effects; Potassium Channels/physiology; Sulfonylurea Compounds/therapeutic use

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Sulfonylurea Compounds / Diabetes Complications / Heart / Heart Diseases / Hypoglycemic Agents Limits: Animals / Humans Language: En Journal: J Am Coll Cardiol Year: 1998 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links